Thursday, December 27, 2012 3:28:44 PM
I understand your concern regarding Allscripts shareholder value and what the future may hold.
Let me offer you some facts for consideration.
First, during the strategic alternatives process, Allscripts Board of Directors conducted a thorough and rigorous review of alternatives. The Board concluded that the best course at this time is to develop Allscripts long-term potential under the direction of a new management team.
Over the coming weeks and months, Paul Black, our new CEO and healthcare IT industry veteran, will work with his leadership team on enhancing our operational efficiency, solutions sales efforts and our financial strategy to ensure that Allscripts is positioned for success and value enhancement.
Regarding your statement on a share repurchase, Allscripts currently has approximately $125MM remaining on its existing $400MM share repurchase authorization announced in May, 2011. Our leadership team is evaluating our capital allocation strategy and will update the market on our Q4 2012 earnings call, which will take place in the mid-February timeframe.
In the meantime, Allscripts fundamentals remain strong – a large client base, strong financial position, one of the industry’s largest investments in R&D, and a refreshed product portfolio based on Open technology.
I hope this perspective is helpful and we again understand and appreciate your concerns as an Allscripts shareholder.
Sincerely,
Seth
Seth R. Frank | Vice President, Investor Relations
Allscripts | 222 Merchandise Mart | Suite 2024 | Chicago, IL | 60654
312.506.1213 | P?
Recent MDRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/03/2024 08:20:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/03/2024 08:20:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/25/2024 08:03:03 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 04/25/2024 01:08:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 10:23:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2024 08:21:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2024 08:21:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2024 11:06:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 11:06:05 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/12/2024 05:53:38 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/08/2024 09:05:23 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/05/2024 02:41:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:42:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:05:56 PM
- Sprinklr Set to Join S&P SmallCap 600 • PR Newswire (US) • 02/28/2024 10:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:55:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:54:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:53:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:07:57 PM
- Veradigm to Participate in TD Cowen Annual Health Care Conference • Business Wire • 02/28/2024 12:00:00 PM
- Veradigm Receives Expected Delisting Notice from Nasdaq • Business Wire • 02/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:16:40 PM
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 02/27/2024 12:08:58 PM
- Veradigm to Acquire ScienceIO • Business Wire • 02/27/2024 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM